These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36362142)

  • 1. Interplay between the DNA Damage Response and Immunotherapy Response in Cancer.
    Lee ECY; Kok JST; Teh BT; Lim KS
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic instability, inflammatory signaling and response to cancer immunotherapy.
    Chen M; Linstra R; van Vugt MATM
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188661. PubMed ID: 34800547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA repair defects in cancer and therapeutic opportunities.
    Hopkins JL; Lan L; Zou L
    Genes Dev; 2022 Mar; 36(5-6):278-293. PubMed ID: 35318271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Damage and Repair Biomarkers of Immunotherapy Response.
    Mouw KW; Goldberg MS; Konstantinopoulos PA; D'Andrea AD
    Cancer Discov; 2017 Jul; 7(7):675-693. PubMed ID: 28630051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair defects and implications for immunotherapy.
    Bever KM; Le DT
    J Clin Invest; 2018 Oct; 128(10):4236-4242. PubMed ID: 30272580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
    Huang JL; Chang YT; Hong ZY; Lin CS
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity.
    Pan D; Wang Q; Shen A; Qi Z; Zheng C; Hu B
    Int J Cancer; 2024 Aug; 155(3):384-399. PubMed ID: 38655783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic instability drives tumorigenesis and metastasis and its implications for cancer therapy.
    Guo S; Zhu X; Huang Z; Wei C; Yu J; Zhang L; Feng J; Li M; Li Z
    Biomed Pharmacother; 2023 Jan; 157():114036. PubMed ID: 36436493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic instability and metabolism in cancer.
    Li H; Zimmerman SE; Weyemi U
    Int Rev Cell Mol Biol; 2021; 364():241-265. PubMed ID: 34507785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA Repair.
    Curigliano G
    Handb Exp Pharmacol; 2018; 249():161-180. PubMed ID: 30341723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular chaperones in DNA repair mechanisms: Role in genomic instability and proteostasis in cancer.
    Hasan A; Rizvi SF; Parveen S; Mir SS
    Life Sci; 2022 Oct; 306():120852. PubMed ID: 35917940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W; Asiaf A; Ahmad ST
    Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous DNA Damage as a Source of Genomic Instability in Cancer.
    Tubbs A; Nussenzweig A
    Cell; 2017 Feb; 168(4):644-656. PubMed ID: 28187286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance.
    Carloni V; Morganti E; Galli A; Mazzocca A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the microRNA-regulating DNA damage/repair pathways in cancer.
    Bottai G; Pasculli B; Calin GA; Santarpia L
    Expert Opin Biol Ther; 2014 Nov; 14(11):1667-83. PubMed ID: 25190496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
    Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
    Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the DNA damage response in immuno-oncology: developments and opportunities.
    Chabanon RM; Rouanne M; Lord CJ; Soria JC; Pasero P; Postel-Vinay S
    Nat Rev Cancer; 2021 Nov; 21(11):701-717. PubMed ID: 34376827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
    Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
    Front Immunol; 2022; 13():943090. PubMed ID: 36081518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response.
    Mardis ER
    Genome Med; 2019 Nov; 11(1):71. PubMed ID: 31747945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
    Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
    Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.